Based on the recent earnings call transcripts, it is recommended to maintain an 'overweight' investment stance on the company. The company's HCV revenues may have decreased, but there are positive indicators for future growth. For example, the company has negotiated new agreements in Europe to expand access to HCV patients. Additionally, the launch of TAF-based regimens has been successful in the U.S. and Europe, and the revenue from this portfolio has shown growth. The company also mentioned that the upcoming launch of their entire TAF portfolio, particularly BIC/TAF and B-F/TAF, is expected to sustain the franchise going forward. Furthermore, there has been a significant uptick in PrEP usage, and persistency in prescribing has improved. In the European market, there has been rapid adoption of TAF-based regimens, and the company expects to see continued growth in this area. Finally, the company's U.S. cardiovascular team continues to deliver impressive results, with Letairis remaining the market leader in PAH and Ranexa ranking in the top five cardiovascular branded products.

Overall, these factors indicate a positive future outlook for the company, and maintaining an 'overweight' investment stance is recommended based on the potential for future growth and sustained revenue in various areas of the company's portfolio.